A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study.
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2014
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Oct 2009 New trial record